GeoVax Labs Files 8-K on Corporate Matters
Ticker: GOVX · Form: 8-K · Filed: May 23, 2024 · CIK: 832489
Sentiment: neutral
Topics: corporate-governance, financial-reporting, filing
Related Tickers: GOVX
TL;DR
GeoVax Labs filed an 8-K detailing corporate governance changes and financial updates.
AI Summary
GeoVax Labs, Inc. filed an 8-K on May 23, 2024, reporting on amendments to its articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The filing indicates changes related to the company's corporate governance and financial reporting.
Why It Matters
This filing provides updates on GeoVax Labs' corporate structure and financial reporting, which are crucial for investors to understand the company's operational and governance status.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate and financial information, not indicating any immediate operational or financial distress.
Key Players & Entities
- GeoVax Labs, Inc. (company) — Registrant
- May 23, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
FAQ
What specific amendments were made to GeoVax Labs' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary information of the 8-K.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided summary.
What financial statements and exhibits are included with this filing?
The filing mentions the inclusion of financial statements and exhibits, but their specific content is not detailed in the summary.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on May 23, 2024.
What is GeoVax Labs, Inc.'s Standard Industrial Classification code?
GeoVax Labs, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 755 words · 3 min read · ~3 pages · Grade level 10 · Accepted 2024-05-23 16:07:35
Key Financial Figures
- $0.001 — ch registered Common Stock , par value $0.001 per share GOVX The Nasdaq Capital Ma
Filing Documents
- govx20240523_8k.htm (8-K) — 48KB
- ex_679029.htm (EX-3.1) — 118KB
- 0001437749-24-018144.txt ( ) — 334KB
- govx-20240523.xsd (EX-101.SCH) — 4KB
- govx-20240523_def.xml (EX-101.DEF) — 13KB
- govx-20240523_lab.xml (EX-101.LAB) — 18KB
- govx-20240523_pre.xml (EX-101.PRE) — 13KB
- govx20240523_8k_htm.xml (XML) — 5KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. As noted at Item 5.07 below, our Stockholders approved an amendment to the Company's Bylaws to reduce the quorum requirements for meetings of stockholders from a majority to thirty-three and one-third percent (33 1/3 %). The Bylaws, as amended, are filed herewith as Exhibit 3.1.
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. The Company held its annual meeting of stockholders on May 23, 2024. The Company received proxies totaling 1,177,811 of its 2,308,309 issued and outstanding shares of common stock as of the record date of March 25, 2024. The stockholders voted on the following proposals and the results of the voting are presented below. Election of Directors Our stockholders voted to elect the slate of directors consisting of seven members to hold office until the next annual meeting of stockholders or until their successors are duly elected and qualified. There were a total of 616,712 broker non-votes on this item. Nominee For Withheld Randal D. Chase 440,096 121,003 David A. Dodd 500,355 60,744 Dean G. Kollintzas 481,762 79,337 Nicole Lemerond 517,969 43,130 Robert T. McNally 476,980 84,119 Jayne Morgan 494,810 66,289 John N. Spencer, Jr. 513,575 47,524 Approval of the Inducement Warrant Exercise Proposal Our stockholders approved a proposal to approve, pursuant to Nasdaq listing rules, the issuance of up to 1,408,998 shares of our common stock upon exercise of a common stock purchase warrant issued to an institutional investor in connect with the Warrant Exercise and Inducement Letter dated December 2, 2023. There were a total of 616,712 broker non-votes on this item. For Against Abstain 480,421 69,206 11,472 Approval of the Bylaws Amendment Proposal Our stockholders approved a proposal to amend the Company's Bylaws to reduce the quorum requirements for meetings of stockholders from a majority to thirty-three and one-third percent (33 1/3 %). There were a total of 616,712 broker non-votes on this item. For Against Abstain 489,102 61,758 10,239 Ratification of Independent Auditor Our stockholders approved the ratification of Wipfli LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024. There were no broker non-vo
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 3.1 Bylaws 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: May 23, 2024 GEOVAX LABS, INC. By: /s/ Mark W. Reynolds Mark W. Reynolds Chief Financial Officer 3